PRUMMER, O and ALEFELDER, J and BERTELS, C and GRAFF, J and HAUPT, G and PASTOR, J and BUTTGEN, A and DROST, KH and FENSTERER, M and TUNN, UW and FROHNEBERG, D and HAUTMANN, R and WENDEROTH, U and BOECKMANN, W and JONAS, D and SCHULDE, H and HARTMANN, H and LEYENDECKER, K and SPARWASSER, H and EISENBERGER, F and HEINZL, R and LUTZ, K and WELLINGER, D and FISCHER, C and HALLWACHS, O and STOCK, U and HUHN, D and MATHEW, M and NAGEL, R and VANHERPE, H and LOHMER, H and MELCHIOR, HJ and HOFMANN, J and SCHNEIDER, W and SCHRAUDENBACH, L and BRAUNCHAURASIA, R and PLANZ, K and VAHLENSIECK, W and WINTER, P and FORSTER, P and WIELAND, W and HASUN, R and MARBERGER, M and BRANDL, H and CHAUSSY, C and LEESER, C and MRSTIK, C and STOGERMAYER, F and BRANDES, V and BUCHSEL, HP and HOPPNER, W and LOPEZGAMARRA, D and ESSER, F and RADEKE, K and WANNER, K and BASTING, R and BERNHARDT, K and KIRCHNER, H and NEISS, A and STORKEL, S and THOENES, W and BULLINGERNABER, M and MANUEL, J and ULM, K and CARMANN, H and DREES, N and HOLDENER, EE and KLOPFER, E and WIEGAND, M and BRAND, I and HEIMPEL, H and POPP, C and PORZSOLT, F and PRUMMER, O and TRAUSCHEL, B (1993) INTERFERON-ALPHA ANTIBODIES IN PATIENTS WITH RENAL-CELL CARCINOMA TREATED WITH RECOMBINANT INTERFERON-ALPHA-2A IN AN ADJUVANT MULTICENTER TRIAL. CANCER, 71 (5). pp. 1828-1834. ISSN 0008-543X,
Full text not available from this repository.Abstract
Background. Prolonged therapy with interferon (IFN) may lead to the formation of IFN antibodies. Methods. Patients with renal cell carcinoma (n = 270) with advanced localized disease were randomized after complete tumor resection to receive treatment with adjuvant recombinant IFN-alpha-2a (rIFN-alpha2a) (9 x 10(6) IU subcutaneously, three times per week for a maximum of 12 months) versus no treatment. Patients (IFN-treated group, 106 patients; control group, 97 patients) were monitored for the presence of rIFN-alpha2a antibodies. Results. Of 86 IFN-treated patients observed for more than 2 months, 40 (47%) had IFN-alpha2a-binding and 25 (29%) had IFN-alpha2a-neutralizing antibodies developed within a median of 3 and 6 months, respectively. A distinct peak in binding antibody titers occurred at 6-9 months. Therapy-induced neutralizing antibodies were equally reactive with two other recombinant IFN-alpha-2 subtypes but poorly recognized natural IFN-alpha (IFN-alpha), recombinant IFN-alpha-1/alpha-8, and recombinant IFN-omega-1. The duration of remission and rate of relapse were independent of the antibody status, although neutralizing and most nonneutralizing antibodies correlated with a reduction in the IFN-induced increase in beta-2-microglobulin levels. Conclusions. Patients treated with IFN-alpha2a should be monitored for the presence and clinical relevance of IFN-alpha antibodies to determine those who could respond to alternative treatment.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ANTITUMOR-ACTIVITY; NEUTRALIZING ANTIBODIES; CLINICAL-SIGNIFICANCE; LEUKEMIA; THERAPY; ALFA-2A; SERUM; INTERFERON-ALPHA; INTERFERON ANTIBODIES; INTERFERON INHIBITORS; BETA-2-MICROGLOBULIN; RENAL CELL CARCINOMA; TREATMENT |
| Depositing User: | Dr. Gernot Deinzer |
| Last Modified: | 19 Oct 2022 08:42 |
| URI: | https://pred.uni-regensburg.de/id/eprint/54080 |
Actions (login required)
 |
View Item |
